PURPOSE: To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS: Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE) and learning and memory (LM). Linear mixed-effects models tested two-way interactions of treatment group (control, chemotherapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way interactions of ApoE (ε4+ v not) by group by time; covariates included baseline age, frailty, race, and cognitive reserve. RESULTS: Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who received chemotherapy having increasingly worse APE scores ( P = .05) and those initiating hormonal therapy having lower LM scores at 12 months ( P = .03) than other groups. These group-by-time differences varied by ApoE genotype, where only ε4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way interaction was not significant ( P = .14), but scores were significantly lower for ε4+ survivors exposed to chemotherapy (-0.40; 95% CI, -0.79 to -0.01) at 24 months than ε4+ controls (0.01; 95% CI, 0.16 to 0.18; P < .05). Increasing age was associated with lower baseline scores on all cognitive measures ( P < .001); frailty was associated with baseline APE and self-reported decline ( P < .001). CONCLUSION: Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with longitudinal decreases in cognitive function scores in older survivors. These data could inform treatment decision making and survivorship care planning.
PURPOSE: To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS: Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE) and learning and memory (LM). Linear mixed-effects models tested two-way interactions of treatment group (control, chemotherapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way interactions of ApoE (ε4+ v not) by group by time; covariates included baseline age, frailty, race, and cognitive reserve. RESULTS: Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who received chemotherapy having increasingly worse APE scores ( P = .05) and those initiating hormonal therapy having lower LM scores at 12 months ( P = .03) than other groups. These group-by-time differences varied by ApoE genotype, where only ε4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way interaction was not significant ( P = .14), but scores were significantly lower for ε4+ survivors exposed to chemotherapy (-0.40; 95% CI, -0.79 to -0.01) at 24 months than ε4+ controls (0.01; 95% CI, 0.16 to 0.18; P < .05). Increasing age was associated with lower baseline scores on all cognitive measures ( P < .001); frailty was associated with baseline APE and self-reported decline ( P < .001). CONCLUSION: Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with longitudinal decreases in cognitive function scores in older survivors. These data could inform treatment decision making and survivorship care planning.
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Ilse Schuitema; Sabine Deprez; Wim Van Hecke; Marita Daams; Anne Uyttebroeck; Stefan Sunaert; Frederik Barkhof; Eline van Dulmen-den Broeder; Helena J van der Pal; Cor van den Bos; Anjo J P Veerman; Leo M J de Sonneville Journal: J Clin Oncol Date: 2013-08-19 Impact factor: 44.544
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Florien W Boele; Christina M T Schilder; Mari-Lou de Roode; Jan Berend Deijen; Sanne B Schagen Journal: Menopause Date: 2015-01 Impact factor: 2.953
Authors: Kevin T Liou; James C Root; Sheila N Garland; Jamie Green; Yuelin Li; Q Susan Li; Philip W Kantoff; Tim A Ahles; Jun J Mao Journal: Cancer Date: 2020-04-22 Impact factor: 6.860
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Young Chandler; Jinani C Jayasekera; Clyde B Schechter; Claudine Isaacs; Christopher J Cadham; Jeanne S Mandelblatt Journal: J Natl Cancer Inst Date: 2020-06-01 Impact factor: 13.506
Authors: Omar Saeed; Lori J Bernstein; Rouhi Fazelzad; Mary Samuels; Lynn A Burmeister; Lehana Thabane; Shereen Ezzat; David P Goldstein; Jennifer Jones; Anna M Sawka Journal: J Cancer Surviv Date: 2019-04-04 Impact factor: 4.442
Authors: Tamar C Demby; Olga Rodriguez; Camryn W McCarthy; Yi-Chien Lee; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck Journal: Behav Brain Res Date: 2020-02-03 Impact factor: 3.332
Authors: Allison Magnuson; Lianlian Lei; Nikesha Gilmore; Amber S Kleckner; Feng V Lin; Robert Ferguson; Arti Hurria; Marsha N Wittink; Benjamin T Esparaz; Jeffrey K Giguere; Jamal Misleh; Javier Bautista; Supriya G Mohile; Michelle C Janelsins Journal: J Am Geriatr Soc Date: 2019-05 Impact factor: 5.562
Authors: Bihong T Chen; Ningrong Ye; Chi Wah Wong; Sunita K Patel; Taihao Jin; Can-Lan Sun; Russell C Rockne; Heeyoung Kim; James C Root; Andrew J Saykin; Tim A Ahles; Andrei I Holodny; Neal Prakash; Joanne Mortimer; Mina S Sedrak; James Waisman; Yuan Yuan; Daneng Li; Jessica Vazquez; Vani Katheria; William Dale Journal: J Geriatr Oncol Date: 2019-11-02 Impact factor: 3.599
Authors: Jennifer L Guida; Tim A Ahles; Daniel Belsky; Judith Campisi; Harvey Jay Cohen; James DeGregori; Rebecca Fuldner; Luigi Ferrucci; Lisa Gallicchio; Leonid Gavrilov; Natalia Gavrilova; Paige A Green; Chamelli Jhappan; Ronald Kohanski; Kevin Krull; Jeanne Mandelblatt; Kirsten K Ness; Ann O'Mara; Nathan Price; Jennifer Schrack; Stephanie Studenski; Olga Theou; Russell P Tracy; Arti Hurria Journal: J Natl Cancer Inst Date: 2019-12-01 Impact factor: 13.506